on August 07, 2026
Brain aging and the progressive deterioration of cognitive functions represent one of the most relevant clinical challenges for modern medicine. Among the primary pathogenic mechanisms identified by contemporary neurobiology, low-grade chronic systemic inflammation — often referred to as inflammaging — plays a leading role in accelerating neurodegeneration.
The accumulation of pro-inflammatory cytokines in the bloodstream, fueled by factors such as visceral obesity, sedentary lifestyle, and metabolic dysfunctions, compromises the permeability of the blood-brain barrier. This triggers microglial activation and the onset of neuroinflammatory phenomena that damage synapses and accelerate neuronal loss, increasing the risk of vascular dementia and Alzheimer's disease [1, 2].
In this scenario, medical-scientific research has focused on integrated strategies capable of acting multimodally: lifestyle modification, neuroprotective phytotherapy, and botanical extracts with anti-inflammatory and vasoactive properties.
Systemic Inflammation and Polyphenolic Modulation: Curcumin
Alongside vasoactive support, countering chronic systemic inflammation represents the second pillar of neuroprotection. Curcumin, a polyphenolic compound extracted from Curcuma longa, has been shown to cross the blood-brain barrier and modulate several inflammatory pathways (including NF-kB, TNF-α, and IL-6).
Research attributes to curcumin the ability to reduce the accumulation of free radicals and inhibit amyloid fibrillogenesis, thereby preventing synaptic dysfunction induced by the systemic pro-inflammatory state [6, 7].
Lifestyle Intervention Models: The FINGER Study
While phytotherapeutic supplementation provides targeted molecular support, lifestyle management forms the foundation upon which the prevention of brain decline rests. This is unequivocally confirmed by the FINGER clinical study (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability), conducted by the Karolinska Institute in Stockholm and published in The Lancet [8].
The study involved approximately 1,300 subjects aged 60 to 77 years at high risk of dementia, divided into two groups:
1. Control Group: Received only standard health advice.
2. Multimodal Intervention Group: Followed an intensive two-year program based on three pillars: physical activity (cardiofitness and muscle strengthening), targeted cognitive training, and a balanced diet.
At the end of the two years, neuropsychological tests showed that the intervention group had a global cognitive score 25% higher than the control group. Specifically:
· Executive functions (planning, reasoning, and problem-solving abilities) were 83% higher.
· Information processing speed showed an increase of 150%.
These data scientifically confirm that the combination of physical activity, mental stimulation, and nutritional modulation can significantly slow down brain aging.
Clinical Aromatherapy and Volatile Molecules for Memory
An area of great interest in modern neuropharmacology concerns the use of essential oils extracted from aromatic plants such as Rosmarinus officinalis, Salvia officinalis, Melissa officinalis, and Zingiber officinale.
The inhalation of essential oils offers substantial pharmacokinetic advantages compared to oral administration:
1. Rapid Absorption: Volatile molecules reach the olfactory mucosa and pass directly to the central nervous system or the bloodstream through the rich pulmonary vasculature.
2. Hepatic Bypass: They avoid hepatic first-pass metabolism, ensuring high plasma bioavailability of terpenic fractions.
Studies conducted on Rosmarinus officinalis and its main constituent, 1,8-cineole (eucalyptol), are particularly relevant. In vitro and in animal models, rosemary extract and essential oil have demonstrated inhibitory action against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes, responsible for the degradation of acetylcholine, a key neurotransmitter in memory and learning processes [9].
In humans, research led by Mark Moss and colleagues has shown that the inhalation of rosemary essential oil produces a significant, dose-dependent improvement in mnemonic performance in healthy subjects [10, 11]. In particular, a direct positive correlation was highlighted between the blood levels of 1,8-cineole absorbed via inhalation and the improvement of prospective memory (both time-based and event-based), i.e., the ability to remember to perform a planned action in the future.
These results confirm a direct pharmacological mechanism of action of 1,8-cineole at the level of the central cholinergic system, independently of simple sensory effects or changes in emotional state and mood.
The Antioxidant and Vasoactive Role of Ginkgo biloba L.
In the field of phytotherapy applied to geriatrics and neurology, Ginkgo biloba L. represents the reference plant species for the prevention and adjuvant treatment of cognitive deficits and cerebral vascular disorders.
The standardized extract from Ginkgo leaves (especially the EGb 761 phytocomplex) exerts a multiple and complex action at the central and peripheral levels:
· Vasoregulatory and Rheological Activity: Promotes arteriolar vasodilation and increases venous tone, improving cerebral microcirculation and capillary resistance. Reduces vascular hyperpermeability, platelet aggregation, and blood hyperviscosity.
· Support for Neuronal Metabolism: Increases glucose and oxygen uptake at the cortical level, stimulating ATP production in impaired neurons.
· Neuroprotection and PAF Inhibition: Sesquiterpenes and diterpenes (particularly ginkgolide B) act as specific inhibitors of platelet-activating factor (PAF), a known pro-inflammatory and neurotoxic mediator. At the same time, flavonoids act as free radical scavengers and inhibit the deposition of beta-amyloid plaques at the level of the cerebral microcirculation [3, 4].
The main international regulatory institutions, including the World Health Organization (WHO), ESCOP (European Scientific Cooperative on Phytotherapy), and the German Commission E, recognize the use of standardized Ginkgo biloba extract in the adjuvant treatment of vascular or degenerative dementias characterized by memory loss, attention deficits, and mood alterations.
In 2014, the European Medicines Agency (EMA) formalized an official monograph indicating Ginkgo biloba dry extract (at a dose of 240 mg per day) for the improvement of age-related cognitive decline and quality of life in the early stages of dementia [5].
Further clinical evidence confirms its efficacy in the treatment of peripheral vascular disorders (intermittent claudication, Raynaud's syndrome), dizziness, and headaches of vascular origin. However, a fundamental clinical warning is highlighted: the concurrent intake of Ginkgo extracts with anticoagulant or antiplatelet drugs (e.g., warfarin, cardioaspirin) enhances their inhibitory effects, requiring careful medical monitoring [4].
Bibliographic References and Scientific Sources
1. Franceschi, C., & Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 69(Suppl_1), S4-S9.
2. Gorelick, P. B. (2010). Role of inflammation in cognitive impairment: implications for vascular cognitive impairment and Alzheimer disease. American Journal of Cardiology, 106(7), 1059-1061.
3. DeFeudis, F. V., & Drieu, K. (2000). Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Current Drug Targets, 1(1), 25-58.
4. Diamond, B. J., et al. (2000). Ginkgo biloba extract: mechanisms and clinical indications. Archives of Physical Medicine and Rehabilitation, 81(5), 668-678.
5. European Medicines Agency (EMA). (2014). European Union herbal monograph on Ginkgo biloba L., folium. EMA/HMPC/321097/2012.
6. Mishra, S., & Palanivelu, K. (2008). The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Annals of Indian Academy of Neurology, 11(1), 13-19.
7. Ringman, J. M., et al. (2012). Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double-blind, placebo-controlled study. Alzheimer's Research & Therapy, 4(5), 43.
8. Ngandu, T., Lehtisalo, J., Solomon, A., et al. (2015). A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet, 385(9984), 2255-2263.
9. Kovar, K. A., et al. (1987). Blood levels of 1,8-cineole and locomotory activity of mice after inhalation and oral administration of rosemary oil. Planta Medica, 53(4), 315-318.
10. Moss, M., Cook, J., Wesnes, K., & Duckett, P. (2003). Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. International Journal of Neuroscience, 113(1), 15-38.
11. Moss, M., & Oliver, L. (2012). Plasma 1,8-cineole correlate with cognitive performance following exposure to rosemary essential oil aroma. Therapeutic Advances in Psychopharmacology, 2(3), 103-113.
